Editor's Note: At OBR we have created an editorial board of renown thought leaders in different cancer disease areas. The role of our editorial board is to provide valuable insights through editorial commentary accompanying our daily news. We call it virtual access. By providing our insights into the daily news, you will have access into how these thought leading oncologists interpret the oncology news and events we carry in OBR daily. We hope that our editorial boards's insights will bring great value to the oncology community.
Professor and Chair, Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Trastuzumab deruxtecan (Enhertu), a HER2-targeting antibody drug conjugate, will represent an import…
Distinguished Professor of Medicine, Rutgers Robert Wood Johnson Medical School
Rutgers-CINJ Associate Director, Clinical Research
Director Clinical Oncology Research, RWJ-B Health System
Kudos to Dr Peter Bach on responding to PhRMA talking points on drug pricing. I am all for R&D …
Executive Director
Community Oncology Alliance
PBMs are getting more brazen in how they delay and deny cancer patients their oral drugs. Anyone in …
National Health Policy Expert
The header for this subject states that while drug/biologic approvals have arrived faster at the FDA…
Professor of Medicine, Division of Hematology/Medical Oncology, School of Medicine
Grover C. Bagby Chair of Prostate Cancer Research
OHSU Knight Cancer Institute Deputy Director, OHSU Knight Cancer Institute, School of Medicine
Chief Medical Officer, CEDAR, OHSU Knight Cancer Institute, School of Medicine
Hot flashes are a common consequence of hormonal therapy for prostate cancer and strategies to treat…
Associate Clinical Professor, Medical Oncology
Executive Director, Employer Services
City of Hope Comprehensive Cancer Center
Duarte, CA
The main limitation I see here is that we're increasingly looking for a wider range of potentially c…
President, W-Squared Group
This piece is a great example of a pathway program in process. Clinical pathways are not meant to b…
Professor and Director, Division of Hematology Oncology
Department of Medicine,Cedars-Sinai Medical Center
Associate Director for Academic Program Development
Samuel Oschin Comprehensive Cancer Institute
Professor of Medicine and Urology, Emeritus
David Geffen School of Medicine at UCLA
This long awaited trial performed by the National Cancer Institute demonstrates the benefits of low …
FACP FACPE FASCO
President, Minnesota Oncology
C-C Chemokine Receptors (CCR5 or CD195) are ubiquitous on immune cells and play a significant role i…
CEO
Tennessee Oncology
I found this article both fascinating and enlightening. I had not thought of "burnout" in terms of …
Vice President
Integrated Community Oncology Network
Former Community Representative
ASCO Board of Directors
So a tale of two cities.....it is interesting to compare the oncology alternative payment model to t…
Florida Cancer Specialists
President and Managing Partner
At Florida Cancer Specialists we have been using DigniCap for several months at 3 of our site and it…
Ronald H. Bloom Chair in Cancer Therapeutics
Professor and Chair, Department of Radiation Oncology
Interim Director, Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Radiotherapy as primary treatment (along with TUR and chemotherapy) is having a bit of a renaissance…
Follow @OBRTweets